Evotec Investor Day Presentation Deck
Clinical
Pre-clinical
evotec
Molecule
EVT201
BAY-1817080
BAY-1817080
BAY-1817080
CT7001
CT7001
EVT401
BAYXXX
BAYXXX
BAY2328065
BI 894416
BI 860585
TPM203
DSP-1181
CNTX 6016
EVT894
BAYXXX
EVT801
APN411
EXS21546
GLPGXXXX
BAYXXXX
QRB001
BMSXXXX
EVT895
EVTXXXX
PAGE 21
Therapeutic Area/Indication
Insomnia (GABA-A)
Chronic cough (P2X3)
Overactive bladder
Endometriosis
Oncology (CDK7)
Oncology (CDK7)
> 100 highly attractive co-owned individual assets
Partnership portfolio pre-clinical and clinical
Immunology & Inflammation (P2X7)
Gynaecology
Multiple indications
Gynaecology
Asthma (not disclosed)
Oncology (m TORC 1/2)
Pemphigus Vulgaris (not disclosed)
Obessive-compulsive disorder (5-HT1A)
Pain (CB2)
Chikungunya (Antibody)
Endometriosis (not disclosed)
Oncology (VEGFR3)
Oncology Immunotherapy
Oncology (various programmes)
Fibrosis (not disclosed)
Nephrology (not disclosed)
Metabolic Diabetes (not disclosed)
Neurodegeneration (not disclosed)
HBV
CNS, Metabolic, Pain ...
Partner
入 京新药业
ENCARMACEUTICAL
Carrick
therapeutics
Carrick
therapeutics
康恩贝集团
CONBA GROUP
Boehringer
Ingelheim
Boehringer
Ingelheim
Topas
Boehringer
Ingelheim
Exscientia
DRIVEN BY KNOWLIGGS
XYNOMIC
Pharma
NIH SANOFI
Galapagos
Therapeutics
SANOFI
SANOFI
Exscientia
DRIVEN BY KNOWLIGGE
QRbeta
THERAPEUTICS
Bristol Myers Squibb
APEIRON
BIOLOGICS
SANOFI
>10 further programmes
Discovery
Pre-clinical
Phase I
1) Not disclosed
Note: Several projects have fallen back to Evotec, where Evotec does not intend to run further clinical trials unpartnered, e.g. EVT302, EVT101, SGM-1019
Phase II
Phase IIIView entire presentation